 Glucagonlike Peptide 1-Based Therapies Associated With Acute Pancreatitis In StudyMain Category: DiabetesArticle Date: 25 Feb 2013 JAMA Internal Medicine Study Highlights In a study by Sonal Singh, M.D., M.P.H., of The Johns Hopkins University School of Medicine, Baltimore, and colleagues, treatment with the glucagonlike peptide-1 (GLP-1)-based therapies sitagliptin and exenatide were associated with increased odds of hospitalization for acute pancreatitis in adults with type 2 diabetes mellitus. (Online First) The population-based case-control study used a large administrative database of adults with type 2 diabetes. Researchers identified 1,269 hospitalized cases with acute pancreatitis and 1,269 matched controls. The average age of the patients was 52 years and almost 58 percent of them were men, according to the study. "In summary, acute pancreatitis has significant morbidity and mortality. In this administrative database study of U.S. adults with type 2 diabetes mellitus, treatment with the GLP-1-based therapies sitagliptin and exenatide was associated with an increased risk of hospitalization for acute pancreatitis," the study concludes. Original article posted on Medical News Today. Articles not to be reproduced without permission of Medical News Today Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles. < back to medical news
|
||||
|
news headlines 
email to a friend 
printer friendly 
sign up to newsletter 
Privacy Policy | Disclaimer | Contact / Feedback
MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2013 All rights reserved.
